A review of the safety of buprenorphine in special populations
Authors:
- 16 July 2022
- journal article
- review article
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 364 (6) , 675-684
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Methadone and Buprenorphine for the Management of Opioid Dependence in PregnancyDrugs, 2012
- Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid-Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched, Randomized, Double-Blind, Placebo-Controlled StudyJournal of Pain and Symptom Management, 2011
- Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsDrug and Alcohol Dependence, 2011
- Neonatal Abstinence Syndrome after Methadone or Buprenorphine ExposureNew England Journal of Medicine, 2010
- A Randomized, Double-Blind, Double-Dummy Comparison of the Efficacy and Tolerability of Low-Dose Transdermal Buprenorphine (BuTrans Seven-Day Patches) With Buprenorphine Sublingual Tablets (Temgesic ) in Patients With Osteoarthritis PainJournal of Pain and Symptom Management, 2010
- Prescribing for older peopleBMJ, 2008
- Interaction between buprenorphine and atazanavir or atazanavir/ritonavirDrug and Alcohol Dependence, 2007
- Transdermal buprenorphine in clinical practice – a post‐marketing surveillance study in 13 179 patientsCurrent Medical Research and Opinion, 2005
- Effects of Liver Disease on PharmacokineticsClinical Pharmacokinetics, 1999
- Pharmacokinetics of Opioids in Liver DiseaseClinical Pharmacokinetics, 1999